Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mobidiag, Genewave and Amplidiag Announce Definitive Agreement

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
The new Mobidiag to offer integrated, high-multiplex diagnostic tests for infectious diseases.

Mobidiag Oy/Ltd, Genewave SAS, and Amplidiag Oy have announced a definitive agreement to combine the three companies to create a technology leader in molecular diagnostics for infectious diseases.

The new Mobidiag combines Mobidiag’s and Amplidiag’s high-multiplex proprietary diagnostic test portfolios with Genewave’s automated and integrated test platform.

The merger was accompanied by a financing round by existing investors Helsinki University Fund, iXLife, Tutor Invest (Medtech Rahasto Ky), and others, as well as public funding support from the Finnish funding agencies, Tekes and Finnvera, and the EU.

Joining as Mobidiag’s new CEO is Tuomas Tenkanen, the former R&D Director of the diagnostics PCR products provider, Finnzymes Oy, which was acquired by Thermo Fisher Scientific.

The transaction was effected as a share exchange, upon which Genewave and Amplidiag became subsidiaries of Mobidiag Oy/Ltd.

The new company is headquartered in Helsinki, with a center of excellence in Paris, and now has the diagnostic test pipeline, integrated test platform, leadership, infrastructure, and financial resources to develop and bring to commercialization its automated instrument and panel of diagnostic tests, capable of identifying a large number of pathogens from a single patient sample.

“The fusion of these three complementary companies creates a unique opportunity to bring forward the next generation of infectious disease diagnostics to dramatically improve global health care,” said Tuomas Tenkanen, CEO, Mobidiag.

Genewave specializes in the development, manufacturing and marketing of cutting-edge microarray instrumentation for diagnostic, clinical and life science research.

Genewave’s innovative GeneSpress® system is an automated and integrated platform for highly multiplexed molecular diagnostic tests.

The compact system integrates DNA purification, PCR amplification and microarray hybridization and detection into an automated workflow on a single, closed lab-on-chip cartridge.

Among other innovative features, the platform incorporates Genewave’s patented TouchArray™ optical detection technology for highly sensitive imaging of microarrays.

Mobidiag’s clinically proven, CE-IVD marked Prove-it™ diagnostic tests enable up to 84 pathogens and antibiotic resistance markers to be detected in a single assay, representing cutting-edge multiplexing capabilities.

Current test products are intended for diagnosing bacterial and fungal sepsis, viral central nervous system infections and bacterial bone and joint infections. Mobidiag has built a reference customer base with its current test portfolio and has generated market acceptance in Europe.

The automation of Mobidiag’s tests will answer the need of clinical laboratories for automated and integrated solutions for diagnostic testing of severe infectious diseases.

Amplidiag provides a broad panel of diagnostic tests for infectious diseases. Amplidiag has substantial intellectual property covering testing and nucleic acid extraction methods for contagious gastrointestinal and other serious diseases.

The global molecular diagnostics market exceeds 5 billion EUR, and is growing more than 15% annually.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mobidiag and Unilabs Enter into Agreement
The agreement solidifies Unilabs’ position as an industry-leading diagnostics service provider and is a major milestone for Mobidiag in European market entry.
Tuesday, September 01, 2015
Mobidiag Announces CE Marking of Amplidiag™ H. pylori+ClariR
Test is first-to-market, non-invasive IVD assay for reliable detection of both Helicobacter pylori and clarithromycin resistance from stool sample.
Wednesday, June 03, 2015
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!